Bortezomib in Treating Patients With Chronic Myelogenous Leukemia
Status:
Terminated
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who
have chronic myelogenous leukemia in chronic or accelerated phase.